CA3174429A1 - Compositions and methods for treatment of acute respiratory distress syndrome - Google Patents

Compositions and methods for treatment of acute respiratory distress syndrome Download PDF

Info

Publication number
CA3174429A1
CA3174429A1 CA3174429A CA3174429A CA3174429A1 CA 3174429 A1 CA3174429 A1 CA 3174429A1 CA 3174429 A CA3174429 A CA 3174429A CA 3174429 A CA3174429 A CA 3174429A CA 3174429 A1 CA3174429 A1 CA 3174429A1
Authority
CA
Canada
Prior art keywords
seq
acid sequence
amino acid
antibody
region
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3174429A
Other languages
English (en)
French (fr)
Inventor
Michael John BROOKS
Blair Richard George GORDON
Pardeep Nijhawan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Edesa Biotech Research Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA3174429A1 publication Critical patent/CA3174429A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/248—IL-6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CA3174429A 2020-04-20 2021-04-20 Compositions and methods for treatment of acute respiratory distress syndrome Pending CA3174429A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202063012783P 2020-04-20 2020-04-20
US202063012786P 2020-04-20 2020-04-20
US63/012,783 2020-04-20
US63/012,786 2020-04-20
US202063081662P 2020-09-22 2020-09-22
US63/081,662 2020-09-22
PCT/CA2021/050544 WO2021212222A1 (en) 2020-04-20 2021-04-20 Compositions and methods for treatment of acute respiratory distress syndrome

Publications (1)

Publication Number Publication Date
CA3174429A1 true CA3174429A1 (en) 2021-10-28

Family

ID=78270861

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3174429A Pending CA3174429A1 (en) 2020-04-20 2021-04-20 Compositions and methods for treatment of acute respiratory distress syndrome

Country Status (8)

Country Link
US (1) US20230192881A1 (cg-RX-API-DMAC10.html)
EP (1) EP4138912A4 (cg-RX-API-DMAC10.html)
JP (1) JP2023523096A (cg-RX-API-DMAC10.html)
CN (1) CN115697410A (cg-RX-API-DMAC10.html)
AU (1) AU2021261060A1 (cg-RX-API-DMAC10.html)
CA (1) CA3174429A1 (cg-RX-API-DMAC10.html)
IL (1) IL297363A (cg-RX-API-DMAC10.html)
WO (1) WO2021212222A1 (cg-RX-API-DMAC10.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12165313B2 (en) * 2019-01-14 2024-12-10 Ark Inc. Deep learning architecture system for automatic fundus image reading and automatic fundus image reading method using deep learning architecture system

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7312320B2 (en) * 2003-12-10 2007-12-25 Novimmune Sa Neutralizing antibodies and methods of use thereof
US7674884B2 (en) * 2003-12-10 2010-03-09 Novimmune S.A. Neutralizing antibodies and methods of use thereof
SI2173381T1 (sl) * 2007-05-14 2014-01-31 Novimmune Sa Fc receptor-vezavni polipeptidi z modificiranimi efektorskimi funkcijami
JP6289098B2 (ja) * 2011-01-10 2018-03-07 ノビミューン エスアー 抗tlr4抗体およびその使用法
HUE037613T2 (hu) * 2012-03-29 2018-09-28 Novimmune Sa Anti-TLR4 antitestek és azok felhasználása
EP3060250A1 (en) * 2013-10-22 2016-08-31 NovImmune SA Methods and compositions for diagnosis and treatment of disorders in patients with elevated levels of tlr4 ligands and other biomarkers
WO2017021552A1 (en) * 2015-08-06 2017-02-09 Novimmune Sa Methods and compositions for identifying patient populations for diagnosis and treatment of tlr4-dependent disorders
EP3519049B1 (en) * 2016-09-30 2025-12-03 Janssen Biotech, Inc. Safe and effective method of treating psoriasis with anti-il23 specific antibody

Also Published As

Publication number Publication date
WO2021212222A1 (en) 2021-10-28
CN115697410A (zh) 2023-02-03
EP4138912A4 (en) 2024-08-07
AU2021261060A1 (en) 2022-11-17
EP4138912A1 (en) 2023-03-01
JP2023523096A (ja) 2023-06-01
IL297363A (en) 2022-12-01
US20230192881A1 (en) 2023-06-22

Similar Documents

Publication Publication Date Title
AU2019218516B2 (en) Antibodies to T cell immunoreceptor with Ig and ITIM domains (TIGIT) and uses thereof
EP2408816B1 (en) Alpha-4-beta-7 heterodimer specific antagonist antibody
CN102046199A (zh) 使用抗mif抗体的治疗方法
AU2021213403B2 (en) Anti-αvβ8 integrin antibodies for use in treating kidney disease
AU2020230333A1 (en) Methods and compositions for diagnosis and treatment of disorders in patients with elevated levels of TLR4 ligands and other biomarkers
AU2016262660A1 (en) Anti-P-selectin antibodies and methods of their use and identification
US10689441B2 (en) Anti—TLR4 antibodies and methods of use thereof
US20230192881A1 (en) Compositions and methods for treatment of acute respiratory distress syndrome
US20170038381A1 (en) Methods and compositions for identifying patient populations for diagnosis and treatment of tlr4-dependent disorders
US20220056137A1 (en) Anti-PD-L1 Binding Proteins and Methods of Use Thereof
JP7603061B2 (ja) Cr2結合タンパク質および医学的治療におけるそれらの使用
AU2016208453A1 (en) Alpha-4-beta-7 heterodimer specific antagonist antibody
US20240018228A1 (en) Antibodies specific to ccl21 and methods of use
WO2025226918A1 (en) Herv-k envelope protein binders and compositions and methods of use thereof
WO2025238052A1 (en) Depletion of plasmacytoid dendritic cells for the treatment of respiratory viral infections
AU2013205341B2 (en) Alpha-4-beta-7 heterodimer specific antagonist antibody

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220930

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD

Year of fee payment: 4

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250328

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250328

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20250402

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20250730

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250801

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250908

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250908

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD

Year of fee payment: 5

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260320

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260320

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20260722